SNMMI

During its 2023 Annual Meeting, the Image of the Year was selected by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), and represents research presented which reports on the ability of a novel theranostic pair to successfully detect metastatic pancreatic cancer and provide a means of selecting appropriate treatments.
News | SNMMI
Image of the Year and Research Announced at SNMMI 2023 on Theranostic Pair for Early Detection and Effective Treatment of Pancreatic Cancer

June 26, 2023 — A first-in-human evaluation of the novel theranostic pair 68Ga-DOTA-5G / 177Lu-DOTA-ABM-5G has confirmed ...

Time June 26, 2023
arrow
A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol degradation in the brain has been successfully validated
News | SNMMI
Translational PET Tracer Visualizes Brain Cholesterol Metabolism

June 25, 2023 — A new PET radiotracer that visualizes the enzyme primarily responsible for metabolic cholesterol ...

Time June 25, 2023
arrow
Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College in Phoenix, Arizona, and nuclear medicine technologist at Banner Staffing Services in Tucson, Arizona, has been elected 2023-24 president-elect for the Society of Nuclear Medicine and Molecular Imaging Technologist Section (SNMMI-TS)
News | SNMMI
SNMMI Announces Julie Dawn Bolin, MS, CNMT, as President-Elect of the Technologist Section During 2023 Annual Meeting

June 25, 2023 — Julie Dawn Bolin, MS, CNMT, program director of nuclear medicine technology at GateWay Community College ...

Time June 25, 2023
arrow
News | SNMMI
Ultra-High Resolution Brain PET Scanner Visualizes and Quantifies Brainstem Nuclei for the First Time

June 24, 2023 — A new ultra-high resolution (UHR) brain PET scanner may have the ability to characterize previously ...

Time June 24, 2023
arrow
 A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has been shown to enhance the image resolution and system sensitivity of clinical whole-body PET/CT imaging.
News | SNMMI
New Whole-Body PET Technology Offers Cost-Effective Solution to Improve Image Resolution and Sensitivity

June 24, 2023 — A newly developed technology called “augmented whole-body scanning via magnifying PET” (AWSM-PET) has ...

Time June 24, 2023
arrow
Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on radiotherapies and theranostics readiness at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2023 Annual Meeting.
News | SNMMI
Cardinal Health Highlights Nuctrac Theranostic Module, Theranostics Readiness at SNMMI 2023

June 23, 2023 — Cardinal Health Nuclear & Precision Health Solutions (NPHS) (Booth #2041) will feature information on ...

Time June 23, 2023
arrow
POSLUMA is now commercially available in multiple U.S. radiopharmacies, with nationwide availability by end of June 2023
News | Prostate Cancer
Blue Earth Diagnostics and PETNET Solutions Inc, A Siemens Healthineers Company, Announce U.S. Commercial Availability of POSLUMA (Flotufolastat F 18) Injection for PET Imaging of Prostate Cancer

June 21, 2023 — Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization ...

Time June 21, 2023
arrow
In March 2023, Appropriate Use Criteria (AUC) for ER-targeted PET imaging was also published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI)
News | Breast Imaging
GE HealthCare Announces FES PET Imaging Recommendation in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)

May 25, 2023 — GE HealthCare, a leader in breast cancer care technology and diagnostics, has today announced that NCCN ...

Time May 25, 2023
arrow
Does a new or increasing contrast enhancement on T1 MRI represent a consequence of treatment or progressive/recurrent tumor? This common clinical dilemma can be resolved by amino acid PET with good diagnostic accuracy.
News | PET Imaging
Amino Acid PET Successfully Differentiates Recurrent Brain Metastases, Reducing Invasive Procedures and Overtreatment

May 12, 2023 — A newly published meta-analysis indicates that amino acid PET can accurately differentiate recurrent or ...

Time May 12, 2023
arrow
newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate the biological changes that cause chemotherapy-related cognitive impairment (CRCI), commonly known as chemo-brain
News | Molecular Imaging
Molecular Imaging Offers Insight Into Chemo-brain

March 29, 2023 — A newly published literature review sheds light on how nuclear medicine brain imaging can help evaluate ...

Time March 29, 2023
arrow
A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an artificial intelligence chatbot, in the field of nuclear medicine and molecular imaging
News | Molecular Imaging
JNM Explores Potential Applications for ChatGPT in Nuclear Medicine and Molecular Imaging

March 28, 2023 — A new article in The Journal of Nuclear Medicine explores the potential for using ChatGPT, an ...

Time March 28, 2023
arrow
A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very fine resolution has been developed and successfully tested, according to research published in the March issue of The Journal of Nuclear Medicine.
News | Nuclear Imaging
New Compact and Low-cost Lensless Radiomicroscope Developed for Nuclear Medicine Imaging

March 22, 2023 — A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very ...

Time March 22, 2023
arrow
A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients
News | Radiopharmaceuticals and Tracers
Pluvicto Supply Shortage Update: What SNMMI is Doing

March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...

Time March 16, 2023
arrow
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of Nuclear Medicine (EANM) have issued a new procedure standard/practice guideline for somatostatin receptor (SSTR) PET imaging for patients with neuroendocrine tumors (NETs).
News | PET Imaging
Procedure Standard/practice Guideline Published for SSTR PET Imaging of Neuroendocrine Tumors

February 23, 2023 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) and the European Association of ...

Time February 23, 2023
arrow
Summary of the pilot study and preliminary PET imaging findings. Image created by R Wetherill, Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA.
News | PET Imaging
PET Imaging Shows Greater Lung Inflammation in e-cigarette Users than Cigarette Smokers

January 31, 2023 — Electronic cigarette (e-cigarette) users have greater lung inflammation than cigarette smokers and ...

Time January 31, 2023
arrow
Summary of imaging findings from the SEER-Medicare linked database for patients with non-small cell lung cancer prior to receiving subsequent radiation therapy. Image created by Emily Sterbis, MD, Interventional Radiology Resident at the University of Colorado
News | Lung Imaging
Nearly Half of Medicare Patients with Non-small Cell Lung Cancer not Staged According to National Guidelines

January 23, 2023 — A study published in the January issue of The Journal of Nuclear Medicine reports that approximately ...

Time January 23, 2023
arrow
This figure highlights 3 patients with a final diagnosis of low-grade uptake (Perugini grade-1). Endomyocardial biopsy results were available for the patient depicted in Panel B demonstrating ATTR-CA as the underlying pathology.
News | Molecular Imaging
Nuclear Medicine Bone Scan Study Identifies Prevalence and Outcomes of Cardiac Amyloidosis

January 5, 2023 — A new study has determined that approximately three percent of all bone scan patients have markers of ...

Time January 04, 2023
arrow
18F-SMBT-1 PET studies showed that beta-amyloid+ Alzheimer’s disease (AD) patients, but most importantly, beta-amyloid+ controls (CN) have significantly higher regional 18F-SMBT-1 binding than beta-amyloid- CN, with 18F-SMBT-1 retention highly associated with beta-amyloid burden. These findings suggest that increased 18F-SMBT-1 binding is detectable at the preclinical stages of beta-amyloid accumulation.
News | PET Imaging
Novel PET Imaging Agent Detects Earliest Signs of Alzheimer's Disease

October 20, 2022 — A new highly selective PET imaging agent can detect the presence of overexpressed monoamine oxidase-B ...

Time October 20, 2022
arrow
Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of Excellence (RTCoE) by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), a distinction held by only 17 centers in the U.S.
News | Radiology Business
Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials

September 8, 2022 — Hoag Memorial Hospital Presbyterian has been named a Radiopharmaceutical Therapy Center of ...

Time September 08, 2022
arrow
Patients with detectable PSA (0.2-2.0 ng/mL) post-prostatectomy considered for salvage radiotherapy undergoing 18F-DCFPyl PSMA PET/CT staging. Image created by M.Ng et al, GenesisCare, Melbourne, Australia.
News | Prostate Cancer
New Research Shows PSMA PET/CT Imaging Changes Management for Close to 50% of Prostate Cancer Patients

September 8, 2022 — In prostate cancer patients experiencing recurrence following a radical prostatectomy, imaging with ...

Time September 08, 2022
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now